Somatic Cancer
Seraseq® HRD gDNA Negative Mix
Details
Resources
Specifications
Frequently Asked Questions
Genomic instability resulting from homologous recombination DNA repair deficiency (HRD) is a response biomarker to assess ovarian and breast cancer patient eligibility for PARP inhibitor and platinum-based therapies. HRD measurements have the potential to improve cancer therapy, however standardizing and democratizing HRD measurements remains challenging due to their inherent complexity. This cell line-derived HRD reference material can support the development, validation, and routine use of assays determining HRD status in cancer patients.
FEATURES
Seraseq gDNA HRD Negative Mix
Seraseq gDNA HRD Mix
Seraseq gDNA HRD Mix Product Sheet
Technical Spreadsheet for Seraseq HRD Reference Materials
Seraseq gDNA HRD Mix Non-Requirement Lette
Seraseq gDNA HRD Negative Mix
#Genomic Instability Score (GIS) calculated using Illumina TruSight™ Oncology (TSO) 500 HRD RUO assay which calculates a GIS using an algorithm licensed from Myriad Genetics. Illumina TSO 500 HRD is not available in Japan.
Solid Tumor FAQs
Review the common questions we receive from our customers and the responses we provide.